Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine Goal Achievement in MDD
NCT02972632Phase 4Completed
- Sponsor
- Takeda
- Start
- Dec 2016
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of vortioxetine in major depressive disorder (MDD), sponsored by Takeda. Primary endpoint: Percentage of Participants Who Achieved Goal Attainment Scale (GAS) Score of >=50 at 12 weeks. Started Dec 2016; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02972632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02972632.